Advertisement
Singapore markets closed
  • Straits Times Index

    3,461.16
    +23.90 (+0.70%)
     
  • S&P 500

    5,564.41
    +59.41 (+1.08%)
     
  • Dow

    40,415.44
    +127.91 (+0.32%)
     
  • Nasdaq

    18,007.57
    +280.63 (+1.58%)
     
  • Bitcoin USD

    66,497.77
    -842.85 (-1.25%)
     
  • CMC Crypto 200

    1,377.75
    -7.51 (-0.54%)
     
  • FTSE 100

    8,222.58
    +23.80 (+0.29%)
     
  • Gold

    2,410.70
    +16.00 (+0.67%)
     
  • Crude Oil

    79.95
    +0.17 (+0.21%)
     
  • 10-Yr Bond

    4.2600
    +0.0210 (+0.50%)
     
  • Nikkei

    39,594.39
    -4.61 (-0.01%)
     
  • Hang Seng

    17,469.36
    -166.52 (-0.94%)
     
  • FTSE Bursa Malaysia

    1,629.68
    +7.61 (+0.47%)
     
  • Jakarta Composite Index

    7,313.86
    -8.12 (-0.11%)
     
  • PSE Index

    6,753.12
    +41.07 (+0.61%)
     

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc.

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company’s presentation will be on Wednesday, June 5 at 3:00 pm ET.

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com